PL3902548T3 - Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu - Google Patents
Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworuInfo
- Publication number
- PL3902548T3 PL3902548T3 PL19839172.4T PL19839172T PL3902548T3 PL 3902548 T3 PL3902548 T3 PL 3902548T3 PL 19839172 T PL19839172 T PL 19839172T PL 3902548 T3 PL3902548 T3 PL 3902548T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- cancer
- egfr inhibitor
- mutant
- resistant egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018247131 | 2018-12-28 | ||
| PCT/JP2019/051377 WO2020138400A1 (en) | 2018-12-28 | 2019-12-27 | L718 and/or l792 mutant treatment-resistant egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3902548T3 true PL3902548T3 (pl) | 2025-07-28 |
Family
ID=69174561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19839172.4T PL3902548T3 (pl) | 2018-12-28 | 2019-12-27 | Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20220072000A1 (pl) |
| EP (1) | EP3902548B1 (pl) |
| JP (1) | JP7303303B2 (pl) |
| KR (1) | KR20210110329A (pl) |
| CN (1) | CN113423403B (pl) |
| AU (1) | AU2019417691B2 (pl) |
| BR (1) | BR112021012687A2 (pl) |
| CA (1) | CA3124750A1 (pl) |
| DK (1) | DK3902548T3 (pl) |
| ES (1) | ES3033635T3 (pl) |
| FI (1) | FI3902548T3 (pl) |
| HU (1) | HUE071862T2 (pl) |
| IL (1) | IL284330B1 (pl) |
| MX (1) | MX2021007852A (pl) |
| PH (1) | PH12021551545A1 (pl) |
| PL (1) | PL3902548T3 (pl) |
| PT (1) | PT3902548T (pl) |
| SG (1) | SG11202106986VA (pl) |
| TW (1) | TWI837266B (pl) |
| WO (1) | WO2020138400A1 (pl) |
| ZA (1) | ZA202104679B (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022007841A1 (zh) * | 2020-07-09 | 2022-01-13 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| US20230372346A1 (en) * | 2020-09-08 | 2023-11-23 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2922077C (en) * | 2013-08-22 | 2018-06-26 | Taiho Pharmaceutical Co., Ltd. | Quinoline-substituted compound |
| CN106687457B (zh) * | 2014-05-13 | 2020-01-10 | 阿里亚德医药股份有限公司 | 用于激酶抑制的杂芳基化合物 |
| JOP20190073A1 (ar) * | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| HUE066587T2 (hu) * | 2017-09-01 | 2024-08-28 | Taiho Pharmaceutical Co Ltd | Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor |
-
2019
- 2019-12-27 PT PT198391724T patent/PT3902548T/pt unknown
- 2019-12-27 TW TW108148114A patent/TWI837266B/zh active
- 2019-12-27 CA CA3124750A patent/CA3124750A1/en active Pending
- 2019-12-27 PL PL19839172.4T patent/PL3902548T3/pl unknown
- 2019-12-27 HU HUE19839172A patent/HUE071862T2/hu unknown
- 2019-12-27 US US17/309,847 patent/US20220072000A1/en active Pending
- 2019-12-27 WO PCT/JP2019/051377 patent/WO2020138400A1/en not_active Ceased
- 2019-12-27 SG SG11202106986VA patent/SG11202106986VA/en unknown
- 2019-12-27 PH PH1/2021/551545A patent/PH12021551545A1/en unknown
- 2019-12-27 EP EP19839172.4A patent/EP3902548B1/en active Active
- 2019-12-27 MX MX2021007852A patent/MX2021007852A/es unknown
- 2019-12-27 CN CN201980087026.5A patent/CN113423403B/zh active Active
- 2019-12-27 JP JP2021530234A patent/JP7303303B2/ja active Active
- 2019-12-27 KR KR1020217023440A patent/KR20210110329A/ko active Pending
- 2019-12-27 BR BR112021012687-2A patent/BR112021012687A2/pt unknown
- 2019-12-27 ES ES19839172T patent/ES3033635T3/es active Active
- 2019-12-27 AU AU2019417691A patent/AU2019417691B2/en active Active
- 2019-12-27 DK DK19839172.4T patent/DK3902548T3/da active
- 2019-12-27 FI FIEP19839172.4T patent/FI3902548T3/fi active
-
2021
- 2021-06-23 IL IL284330A patent/IL284330B1/en unknown
- 2021-07-05 ZA ZA2021/04679A patent/ZA202104679B/en unknown
-
2025
- 2025-01-10 US US19/015,893 patent/US20250144103A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019417691B2 (en) | 2025-07-10 |
| PH12021551545A1 (en) | 2022-08-15 |
| CN113423403B (zh) | 2025-02-18 |
| EP3902548A1 (en) | 2021-11-03 |
| DK3902548T3 (da) | 2025-07-07 |
| US20250144103A1 (en) | 2025-05-08 |
| KR20210110329A (ko) | 2021-09-07 |
| US20220072000A1 (en) | 2022-03-10 |
| FI3902548T3 (fi) | 2025-07-17 |
| PT3902548T (pt) | 2025-06-27 |
| AU2019417691A1 (en) | 2021-07-22 |
| WO2020138400A1 (en) | 2020-07-02 |
| IL284330B1 (en) | 2025-11-01 |
| ES3033635T3 (en) | 2025-08-06 |
| CA3124750A1 (en) | 2020-07-02 |
| JP7303303B2 (ja) | 2023-07-04 |
| EP3902548B1 (en) | 2025-05-28 |
| MX2021007852A (es) | 2021-08-11 |
| TW202038965A (zh) | 2020-11-01 |
| SG11202106986VA (en) | 2021-07-29 |
| TWI837266B (zh) | 2024-04-01 |
| ZA202104679B (en) | 2023-12-20 |
| HUE071862T2 (hu) | 2025-09-28 |
| CN113423403A (zh) | 2021-09-21 |
| BR112021012687A2 (pt) | 2021-09-28 |
| JP2022522573A (ja) | 2022-04-20 |
| IL284330A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| IL281999A (en) | YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy | |
| SI4014976T1 (sl) | Aprocitentan za uporabo pri zdravljenju hipertenzije in sorodnih bolezni v kombinaciji z valsartanom | |
| IL279347A (en) | Gremlin-1 antagonist for cancer prevention and treatment | |
| IL283938A (en) | Compounds and their use in the treatment of a1-antitrypsin deficiency | |
| IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| PL3902548T3 (pl) | Inhibitor egfr z powodującą oporność na leczenie mutacją l718 i/lub l792 do stosowania w leczeniu nowotworu | |
| LT4340842T (lt) | Sotorasibas, skirtas naudoti vėžio gydymui | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| HUE055747T2 (hu) | EGFR-gátló és MEK-gátló kombinációja NRAS-mutált rák kezelésében történõ alkalmazásra | |
| IL276668A (en) | Thioredoxin reductase inhibitors for use in the treatment of cancer | |
| SG11202107720UA (en) | Cnx/erp57 inhibitor for use in the treatment or prevention of cancer | |
| GB201918404D0 (en) | Compounds and their use for the treatment of aplha1-antitrypsin deficiency | |
| IL287050A (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
| IL286649A (en) | The history of quinoline and its use in cancer treatment | |
| IL280262A (en) | Compositions and methods for treating cancer | |
| HUP1900281A1 (hu) | Monoamin-oxidáz-B gátlók prosztata karcinóma megelõzésében vagy kezelésében történõ alkalmazásra | |
| IL277112A (en) | Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer | |
| AU2019902712A0 (en) | Inhibitors and use thereof in cancer treatment | |
| GB201908110D0 (en) | Compositions and methods for use in the treatment of cancer-related fatigue | |
| HK40063212A (en) | Phagocytisable particle for use in the treatment or prophylaxis of cancer | |
| GB201820455D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820452D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820451D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| HK40020424A (en) | Sulfinylpyridines and their use in the treatment of cancer |